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In 2016, immune checkpoint inhibitors entered the 
therapeutic portfolio of squamous cell carcinoma of the 
head and neck (SCCHN) in the second-line recurrent and/
or metastatic setting, and it took another three years that the 
long-awaited results of the first-line KEYNOTE-048 trial 
demonstrated superiority relative to the standard cytotoxic 
doublet with cetuximab (1-3). As for a brief historical 
review, the combination of a platinum derivate, preferably 
cisplatin, and 5-fluorouracil emerged as a reference 
regimen for recurrent and/or metastatic SCCHN already 
in 1980s, although its impact on overall survival has rather 
been assumed on a basis of extrapolations than proved in 
large randomized trials (4). The major turning point came 
when the results of the EXTREME trial (Erbitux in first-
line treatment of recurrent or metastatic head and neck 
cancer) were published back in 2008. Adding cetuximab, a 
monoclonal antibody against the epidermal growth factor 
receptor (EGFR), to a platinum/5-fluorouracil combination 
improved overall survival by almost 3 months at acceptable 
toxicity rates and no cetuximab-related deaths (3). Since 
then, the 10-month median survival mark achieved by 
EXTREME has repeatedly been confirmed in several large 
randomized trials using this regimen in the comparator 
arm (2,5,6). However, this progress related only to the first-
line setting in platinum-sensitive patients. At that time, the 
outcomes of second-line treatment remained bleak with an 
expected median survival of 3 to 6 months (7).
This changed in 2016. The immune checkpoint 
inhibitor nivolumab, an immune-modulating monoclonal 
antibody against programmed cell death protein-1 (PD-1), 
became the first drug ever to significantly prolong 
median overall survival to about 8 months in platinum-
resistant patients enrolled in the CheckMate-141 trial (1). 
Using pembrolizumab, another anti-PD-1 agent, this 
benefit was reproduced in the succeeding KEYNOTE-040 
trial. Besides that, the latter trial introduced a long-
awaited predictive biomarker, albeit originating from an 
exploratory analysis. With a P value for interaction of 0.015, 
the tumour proportion score (TPS), corresponding with 
the percentage of tumour cells with membranous staining 
of the ligand for PD-1 (PD-L1), of 50% or more was 
associated with improved benefit in comparison to a lower 
expression, particularly with respect to survival and tumour 
response (8). Subsequently, high hopes were put into the 
first-line administration of immune checkpoint inhibitors. 
The KEYNOTE-048 trial randomly assigned platinum-
sensitive patients to receive either the standard of care, i.e., 
the EXTREME regimen, or a single-agent pembrolizumab, 
or a combination of the two, i.e., a platinum/5-fluorouracil 
doublet with pembrolizumab (2). 
While the primary hypothesis of the two former 
immunotherapy studies focused solely on the superiority 
of the respective immune checkpoint inhibitors for 
overall survival, there were in total 14 primary hypotheses 
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tested in KEYNOTE-048 both for progression-free and 
overall survivals, which emerged after four changes in the 
original protocol of the latter study. Using superiority or 
non-inferiority design according to selected hypothesis, 
the applied statistical analyses compared the standard-
of-care arm with either pembrolizumab alone or 
pembrolizumab associated with chemotherapy, but not 
the two immunotherapy arms between each other. In 
2016, more than one year after the KEYNOTE-048 start 
date, the fifth out of ten protocol amendments updated 
the pre-specified biomarker from TPS to the combined 
positive score (CPS). This modification was supported by 
preliminary results from two previous phase I-II studies, 
KEYNOTE-012 and KEYNOTE-055, which showed 
that inclusion of inflammatory cells, next to neoplastic 
cells, into PD-L1 scoring improves its predictive capacity 
for response, particularly when related to CPS cutpoints 1 
and 20. Subsequently, the analyses were run separately in 
CPS ≥20, CPS ≥1, and total populations. The final efficacy 
and toxicity outcomes are summarized in Table 1 (1,2,8,9). 
Based on overall survival results, the authors concluded that 
pembrolizumab with chemotherapy should be considered 
the new standard in the first-line palliative setting, whereas 
pembrolizumab alone can be recommended for PD-L1 
positive tumours (2).
However, the seemingly decreasing efficacy in analyses 
of populations with more patients having lower CPS, which 
becomes apparent when moving from CPS ≥20 to CPS ≥1 
and then to total populations, incited questions about the 
benefit of immunotherapy in tumours with lower PD-L1 
expression. Such subgroup analyses were not included in the 
peer-review publication but are available in an assessment 
report of the European Medicines Agency dating from 
October 17, 2019 (10). Here, the following information 
can be retrieved. In the CPS <1 subgroup, overall survival 
advantage was found neither in the comparison between 
pembrolizumab alone and EXTREME [7.9 vs. 11.3 months, 
respectively, hazard ratio (HR), 1.51; 95% confidence 
interval (CI), 0.96–2.37] nor between pembrolizumab/
chemotherapy and EXTREME (11.3 vs. 10.7 months, 
respectively, HR, 1.21; 95% CI, 0.76–1.94). In the CPS ≥1 
to CPS <20 population, the benefit was confined only to 
the pembrolizumab/chemotherapy combination (12.7 vs. 
9.9 months, respectively, HR, 0.71; 95% CI, 0.54–0.94) but 
not pembrolizumab monotherapy (10.8 vs. 10.1 months, 
respectively, HR, 0.86; 95% CI, 0.66–1.12). Owing to 
insufficient power, the results of such post-hoc analyses are 
likely to be biased and should be thus regarded with caution. 
Nonetheless, they can still be considered hypothesis 
generating and provide in fact a plausible explanation for 
the observed correlation between PD-L1 expression and 
treatment effect.
Pros and cons of immunotherapy
Beyond any doubt, immune checkpoint inhibitors 
represent the therapeutic highlight of the past decade. 
They demonstrated clinical activity in heavily pre-
treated patients after several previous chemotherapy 
lines, including platinum-resistant cases (1,8,11). Their 
generally mild toxicity profile exempt from most of the 
typical chemotherapy-related adverse events allow a 
safe and effective administration in elderly and probably 
also frail patients as shown in non-small-cell lung and 
urothelial cancers, respectively (12-15). Furthermore, 
nivolumab delayed time to quality of life deterioration 
in CheckMate-141 (1). However, they won recognition 
primarily for the encouraging long-term outcomes and 
complete responses, particularly in malignant melanoma. 
In CheckMate-141, less than 10% of patient population 
were expected to be alive after 3 years from treatment 
initiation (9). In KEYNOTE-048, longer follow-up is still 
needed, yet the plateau-phase of the presented survival 
curves strongly suggests the existence of a larger proportion 
of patients who may still be alive even at 5 years (2).
Although the rationale behind immunotherapy, that is 
to strengthen the immune system in the defence against 
cancer, seems to be a reasonable approach in almost 
every individual, the current armamentarium leaves many 
questions open. One of the greatest fears when treating 
patients with symptomatic unresectable tumour is the 
risk of progression. Local and/or regional recurrences of 
head and neck cancer often fulfil these criteria due to their 
growth in a relatively small, aesthetically exposed area near 
vital structures. The KEYNOTE-048 trial showed that the 
rate of progressive disease in both immunotherapy arms was 
numerically higher than in the EXTREME arm irrespective 
of CPS. Noteworthy, this rate remains relatively constant 
at about 40% when anti-PD-1 agents are used alone in 
both the first- and second-line settings (Table 1). We may 
speculate about the relationship between such progression 
and the lack of survival benefit brought by immunotherapy 
in patients presenting with local and/or regional recurrence 
only as seen in all KEYNOTE-048 subgroups (2). The 
perils of progression are further amplified by the risk 
of an accelerated tumour growth, also known as hyper 
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progression, which may occur in as much as 25–29% of 
cases (16,17).
Despite the overall reassuring toxicity profile of immune 
checkpoint inhibitors, the adverse events might be more 
frequent than first thought and the reported treatment-
related severe acute toxicity of 12% to 16% in the single-
agent use thus underestimated (Table 1). This assumption 
is based on administrative claims data, on health-related 
quality of life scores, and more recently on the rate of all-
cause grade 3–4 toxicity in KEYNOTE-048 reaching up to 
46% in the pembrolizumab alone arm (2,4). Although data 
on all-cause toxicity are missing in CheckMate-141 and 
KEYNOTE-040, the discrepancy between the treatment-
related and all-cause side effects in KEYNOTE-048 may 
reflect the downside of subjective toxicity evaluation by 
investigators but also the difficulty of recognizing the so 
called immune-related adverse events. Treatment-related 
mortality remains very low in the experimental arms but 
is still numerically higher than in the chemotherapy arms 
when looking at the two second-line trials (2 vs. 1 and 
4 vs. 2 deaths, respectively) and at the pembrolizumab/
chemotherapy arm against EXTREME in KEYNOTE-048 
(11 vs. 8, respectively). Whether this subtle but noticeable 
increment in the risk of death has any meaning is really 
speculative, yet a consistent finding (1,2,8).
Moreover, mounting evidence, albeit retrospective or 
arising from indirect prospective comparisons, suggests non-
inferiority of simultaneous versus sequential administration 
of chemotherapy and immunotherapy. This is in line 
with recent pharmacological findings suggesting that at a 
mechanistical level, clinical efficacy of many combination 
regimens is conferred by independent drug action without 
interaction (i.e., without additivity or synergy) (18). Indeed, 
the efficacy seems to be preserved or even improved with 
sequential versus simultaneous treatment and the risks 
of premature progression or immune-related side-effects 
reduced (4,19). In this respect, the choice of first-line 
cytotoxics, such as taxanes, may play an important role (20). 
It’s also worth mentioning that in KEYNOTE-048, patients 
allocated to EXTREME received more frequently second-
line therapy (in 53%) than it was the case in the other two 
arms (49% after pembrolizumab monotherapy and 41% 
after pembrolizumab/chemotherapy regimen) (2). 
However, there are some more unanswered questions 
following the KEYNOTE-048 report. First, a direct 
comparison between the two immunotherapy arms 
would help us better define the role of the individual 
therapeutic approaches. While in the total population and 
the CPS ≥1 group, overall survival was the highest in the 
pembrolizumab/chemotherapy arm, intermediate in the 
pembrolizumab arm, and the lowest in the EXTREME arm; 
in the CPS ≥20 group, pembrolizumab monotherapy yielded 
the longest survival, even better than pembrolizumab/
chemotherapy. Understanding the shorter-than-expected 
survival in the latter arm could be crucial for treatment 
sequencing. In addition, the authors stated that there were 
more long-term survivors than was the proportion of long-
term responders. Again, more detailed information would be 
welcomed, including disease characteristics and subsequent 
treatments in the respective subgroups. This holds also for 
the used platinum derivates because we learned from the 
EXTREME trial that cisplatin generates more responses 
than carboplatin and the overall survival benefit of adding 
cetuximab to platinum/5-fluorouracil doublet was limited 
to those who received cisplatin (3,7). Given that carboplatin 
was chosen for the majority of chemotherapy-receiving 
patients in KEYNOTE-048, it is of major interest to know 
the differences in responses and survival between these two 
drugs. In particular, it might have important implications if 
cisplatin was able to overcome at least some of the (hyper)
progressions on immunotherapy, especially in local and/or 
regional recurrences.
New treatment algorithm for 2020
Due to the distinct pharmacodynamic features of immune 
checkpoint inhibitors, there are several factors impacting 
on the decision-making process in the recurrent and/
or metastatic setting as depicted in Figure 1. Platinum 
compounds represent the chemotherapeutic backbone 
in palliative but also curative protocols and a distinction 
between platinum-sensitive and platinum-refractory 
disease has to be therefore made in the first place. Then 
we implemented four continuous functions which help 
steer our therapeutic preference to either chemotherapy 
or immunotherapy or in the context of first-line platinum-
sensitive disease also to a combination of these two. These 
include pathologically determined CPS (from high to low) 
and clinically assessed biological age (from fitness to frailty), 
disease burden (from high to low), and pace of the disease 
(from fast to slow). The clinical utility of CPS has already 
been described above. We would like to stress that the given 
cut-off values are not to be regarded as a dogma. The results 
can be biased by tumour heterogeneity, inter-observer 
variability, and other possible methodological issues (21,22). 
This comes forward when dealing with borderline values 
Annals of Translational Medicine, Vol 8, No 15 August 2020 Page 5 of 8
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2020;8(15):975 | http://dx.doi.org/10.21037/atm.2020.03.164
F
ig
ur
e 
1 
Sy
st
em
ic
 t
re
at
m
en
t 
al
go
ri
th
m
 f
or
 r
ec
ur
re
nt
 a
nd
/o
r 
m
et
as
ta
ti
c 
sq
ua
m
ou
s 
ce
ll 
ca
rc
in
om
a 
of
 t
he
 h
ea
d 
an
d 
ne
ck
 o
ut
si
de
 c
lin
ic
al
 t
ri
al
s.
 *
ot
he
r 
dr
ug
s 
th
at
 c
an
 b
e 
su
gg
es
te
d 
in
cl
ud
e 
m
et
ho
tr
ex
at
e,
 a
fa
tin
ib
, o
r 
pa
lb
oc
ic
lib
 w
ith
 c
et
ux
im
ab
 a
s 
su
m
m
ar
iz
ed
 in
 (
4)
. †
pe
m
br
ol
iz
um
ab
 c
an
 b
e 
us
ed
 in
 p
at
ie
nt
s 
w
ho
 p
ro
gr
es
se
d 
w
ith
in
 3
–6
 m
on
th
s 
af
te
r 
co
m
pl
et
in
g 
pl
at
in
um
-b
as
ed
 c
he
m
or
ad
io
th
er
ap
y 
es
pe
ci
al
ly
 if
 T
P
S 
≥5
0%
. P
FE
, p
la
tin
um
/5
-fl
uo
ro
ur
ac
il/
ce
tu
xi
m
ab
 r
eg
im
en
 a
cc
or
di
ng
 t
o 
th
e 
E
X
T
R
E
M
E
 t
ri
al
; T
P
E
x,
 
do
ce
ta
xe
l/
pl
at
in
um
/c
et
ux
im
ab
 r
eg
im
en
; P
D
-L
1,
 li
ga
nd
 fo
r 
pr
og
ra
m
m
ed
 c
el
l d
ea
th
 p
ro
te
in
-1
; e
sp
., 
es
pe
ci
al
ly
; T
P
S,
 tu
m
ou
r 
pr
op
or
tio
n 
sc
or
e;
 5
-F
U
, 5
-fl
uo
ro
ur
ac
il.
A
cc
or
di
ng
 to
 p
re
vi
ou
s 
pl
at
in
um
 a
dm
in
is
tr
at
io
n 
fo
r 
lo
co
re
gi
on
al
ly
 a
dv
an
ce
d 
di
se
as
e
P
la
tin
um
-s
en
si
tiv
e 
(>
6 
m
on
th
s)
 o
r 
na
iv
e
If 
pr
ev
io
us
 c
he
m
ot
he
ra
py
P
la
tin
um
-s
en
si
tiv
e
P
em
br
ol
iz
um
ab
(e
sp
. i
f T
P
S
 ≥
50
%
)
M
on
ot
he
ra
py
 o
r
co
m
bi
na
tio
n 
of
pl
at
in
um
, t
ax
an
e,
 5
-
FU
, o
r 
ot
he
r 
dr
ug
(s
)*
P
la
tin
um
-r
es
is
ta
nt
N
iv
ol
um
ab
or
 p
em
br
ol
iz
um
ab
(e
sp
. i
f T
P
S
 ≥
50
%
)
Ta
xa
ne
 if
 n
ot
re
ce
iv
ed
 p
re
vi
ou
sl
y
or
 o
th
er
 d
ru
g(
s)
*
P
la
tin
um
-s
en
si
tiv
e
M
on
ot
he
ra
py
 o
r
co
m
bi
na
tio
n 
of
pl
at
in
um
, t
ax
an
e,
5-
FU
, o
r 
ce
tu
xi
m
ab
O
th
er
 d
ru
g(
s)
*
P
la
tin
um
-r
es
is
ta
nt
Ta
xa
ne
 ±
 c
et
ux
im
ab
C
et
ux
im
ab
m
on
ot
he
ra
py
or
 o
th
er
 d
ru
g(
s)
*
P
re
fe
rr
ed
A
lte
rn
at
iv
el
y
N
iv
ol
um
ab
or
 p
em
br
ol
iz
um
ab
(e
sp
. i
f T
P
S
 ≥
50
%
)
C
et
ux
im
ab
 m
on
ot
he
ra
py
 if
 n
ot
 re
ce
iv
ed
 in
th
e 
pr
ev
io
us
 li
ne
 o
r 
ot
he
r 
dr
ug
(s
)*
Ta
xa
ne
 ±
 c
et
ux
im
ab
C
et
ux
im
ab
 m
on
ot
he
ra
py
, p
la
tin
um
re
ch
al
le
ng
e,
 o
r 
ot
he
r 
dr
ug
(s
)*
If 
pr
ev
io
us
 im
m
un
ot
he
ra
py
±
 c
he
m
ot
he
ra
py
If 
pr
ev
io
us
 c
he
m
ot
he
ra
py
If 
pr
ev
io
us
ly
 im
m
un
ot
he
ra
py
D
ec
is
io
n-
m
ak
in
g
fa
ct
or
s
B
io
lo
gi
ca
l a
ge
Tu
m
ou
r 
bu
rd
en
D
is
ea
se
 p
ac
e
P
D
-L
1 
ex
pr
es
si
on
Im
m
un
ot
he
ra
py
(p
re
fe
rr
ed
)
fit
hi
gh fa
st
lo
w
fit
hi
gh fa
st
lo
w
fr
ai
l
lo
w
sl
ow
hi
gh
fr
ai
l
lo
w
sl
ow
hi
gh
P
la
tin
um
-r
es
is
ta
nt
 (≤
6 
m
on
th
s)
FI
R
S
T-
LI
N
E
 S
Y
S
T
E
M
IC
 T
R
E
A
T
M
E
N
T
S
E
C
O
N
D
-L
IN
E
 S
Y
S
T
E
M
IC
 T
R
E
A
T
M
E
N
T
C
he
m
ot
he
ra
py
Im
m
un
ot
he
ra
py
C
he
m
o-
im
m
un
ot
he
ra
py
P
FE
 (p
re
fe
rr
ed
),
TP
E
x 
or
 o
th
er
P
F-
pe
m
br
ol
iz
um
ab
P
em
br
ol
iz
um
ab
Ta
xa
ne
 ±
 c
et
ux
im
ab
N
iv
ol
um
ab
or
 p
em
br
ol
iz
um
ab
†
C
he
m
ot
he
ra
py
Szturz and Vermorken. Translating KEYNOTE-048 into practice
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2020;8(15):975 | http://dx.doi.org/10.21037/atm.2020.03.164
Page 6 of 8
around the predefined cut-off levels. At the same time, 
we should not forget that high CPS does not equate with 
tumour response, albeit we lack detailed analyses stratified 
according to CPS above the cutpoint 20.
Biological age has already been mentioned in connection 
with arguments in favour of immunotherapy in frail persons. 
Although typically associated with advancing age (≥70 years) 
and involuntary weight loss (≥5% in one year), frailty can 
even exist in younger people, especially cancer patients. 
Appropriate indication of screening tests and geriatric 
assessment tools that encompass a thorough interdisciplinary 
appraisal contributes to personalisation of cancer care (23). 
The last two variables, burden and pace of the disease, 
have been introduced to address the low response rate and 
high risk of progression observed in patients treated with 
immunotherapy alone in comparison with cytotoxic agents. 
Typically relying on individual clinical judgement and 
imaging modalities, no standardized methods or scales have 
been validated for their measurement. Therefore, patients 
with a bulky, widespread, or rapidly progressive disease 
might rather be considered for a regimen incorporating 
chemotherapy. In this respect, the presence or absence of 
symptoms, organ dysfunctions, or their imminent threat 
can serve as a good guiding clue. Notably, the median time 
to response was comparable between immunotherapy and 
chemotherapy in KEYNOTE-048 and CheckMate-141 but 
was longer in the pembrolizumab arm in KEYNOTE-040 
(median: 4.5 vs. 2.2 months) (1,2,8). A different concept 
applies to an indolent or oligoprogressive disease. Here, 
early systemic treatment initiation should be weighed against 
the use of local ablation strategies (4). Some investigators 
even question that in all circumstances early intervention is 
always better than delayed initiation of treatment (24).
Opting for a drug class or a combination thereof is 
followed by selecting a treatment regimen or enrolling the 
patient in a clinical trial. Immune checkpoint inhibitors 
validated for SCCHN have been limited to two anti-PD-1 
agents so far. In principle, nivolumab and pembrolizumab 
are interchangeable, and the inconsistency in biomarker 
recommendations (CPS, TPS, or none in CheckMate-141) 
is primarily driven by the respective trial designs (25). 
On the other hand, the choice of chemotherapeutics can 
be more challenging. According to local regulations and 
policies, the standard first-line regimen for platinum-
sensitive patients, EXTREME, has often been modified 
or replaced by taxane-containing protocols. Prioritizing 
cisplatin before carboplatin can improve local control in 
symptomatic and/or bulky disease. In the second line, 
no randomized trials demonstrated a superiority of one 
chemotherapy over another. With this limitation in 
mind, taxanes alone or in combination, for example, with 
cetuximab seem to provide a clinically relevant benefit (4). 
In BERIL-1, a randomized phase II trial, paclitaxel plus 
placebo achieved a disease control rate of 70% with 
only one quarter of patients who had progression as 
their best response (26). A subgroup analysis of both 
second-line immunotherapy trials, CheckMate-141 and 
KEYNOTE-040, found no survival difference between the 
PD-1 inhibitor and single-agent docetaxel (1,8). Last but 
not the least, based on disease-control rates of about 50% 
and acceptable toxicity profile, cetuximab monotherapy is 
reimbursed in some countries in the second line, although 
its benefit might be limited to human papillomavirus 
(HPV)-negative disease (27).
Conclusions and future outlooks
The purpose of our treatment algorithm is to show the 
complexity of therapeutic landscape in recurrent and/
or metastatic SCCHN and propose possible options in 
sequencing of systemic treatment. It is critical to recognize 
that all of the presented decision-making factors (excluding 
platinum-sensitivity/resistance) are continuous variables 
and should all be taken into account conjointly while 
respecting patient autonomy and local resources. In view of 
profound inequities in the accessibility of modern therapeutic 
approaches across the globe, the latter factor cannot be 
underestimated. However, good availability and affordability 
of immunotherapy per se do not guarantee an optimal 
cancer care and may sometimes even be harmful, such as 
when treatment recommendations are adopted prior to peer-
review publications, especially in the context of accumulating 
negative results from other immunotherapy trials 
(Active8, CONDOR, EAGLE, and CheckMate-714) (28). 
Nevertheless, we remain optimistic and look forward to the 
upcoming reports of KEYNOTE-048 and other exciting 
news in the field of cancer immunotherapy.
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